Skip to Content

SHARE

Clinical Trials Details

VITAL

A Randomized, Double-Blind, Placebo-Controlled Phase II/III Trial of Vigil Augumented Autologous Tumor Cell Immunotherapy in Subjects with Stage III/IV Ovarian Cancer in Clinical Complete Response following Surgery and Primary Chemotherapy (VITAL)

Objective

Part I Patient consents for tissue collection at time of surgery.

No neo-adjuvant therapy is allowed prior to tissue collection.

Presumptive Stage III/IV high grade serous/endometrioid ovarian, fallopian tube or primary peritioneal cancer

Part II Completion of primary surgical debulking and at least 5 by no more than 6 cycles platinum/taxane adjuvant chemotherapy.

Clinically defined Complete Response following completion of therapy.

Must initiate adjuvant chemotherapy no more than 8 weeks following surgery.

 

 

IRB Protocol Number
CL-PTL-119
Contact
Judy Miller, RN CCRP at 406-435-7482
or jmiller4@billingsclinic.org

Location

  • Billings Clinic Hospital Fountain Courtyard - South of the Hospital Cafeteria
    2750 9th Ave North
    Billings, MT 59101